Thank you for your participation in the 1002-CL-0101 clinical study, a phase 1 study for ASP1002 in patients with metastatic or locally advanced solid tumors. Your experiences in this study are important to us and we would like to hear about them. You are not required to complete this survey as part of your participation in the study, and your decision to fill it out or not will have no impact on your continuing study participation. If you choose to complete the survey, your answers will help us improve future studies. There are no right or wrong answers, and it will take approximately 10 minutes to complete. The survey will not use your name or other identifying information. We thank you in advance for your feedback.